Phio Pharmaceuticals Corp. (PHIO)Healthcare | Biotechnology | King of Prussia, United States | NasdaqCM
1.13 USD
+0.01
(0.893%)
⇧
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 1.12 -0.01 (-0.010%) ⇩ (Aug. 28, 2026, 6:50 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 3:04 a.m. EDT
The immediate outlook remains neutral despite a recent price bounce, as the stock trades near its 50-day average but lacks the explosive momentum required for a bullish entry. The statistical forecast offers no directional edge, reflecting the inherent volatility of small-cap biotech plays. However, the long-term investment case is severely compromised by a decade of continuous annual declines and a cumulative loss of nearly 100%, signaling a structural deterioration where the market has repeatedly rejected the business model. While analysts project a massive recovery to $14, this target relies entirely on a successful clinical trial outcome rather than proven fundamentals, as the company burns significant cash with negative returns on equity and assets. There is no dividend income to offset the capital risk, making this a speculative gamble on a binary event rather than a sound investment. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.137275 |
| MSTL | 0.181523 |
| AutoETS | 0.185673 |
| AutoARIMA | 0.188411 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 40% |
| H-stat | 19.45 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.596 |
| Excess Kurtosis | -0.51 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 13,127,494 |
| Forward P/E | -1.85 |
| Beta | 0.79 |
| Website | https://phiopharma.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.4716981 |
| Address1 | 411 Swedeland Road |
| Address2 | Suite 23-1080 |
| All Time High | 6,379,560.0 |
| All Time Low | 0.813 |
| Ask | 1.13 |
| Ask Size | 1 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 221,900 |
| Average Daily Volume3 Month | 625,240 |
| Average Volume | 625,240 |
| Average Volume10Days | 221,900 |
| Beta | 0.787 |
| Bid | 0.8208 |
| Bid Size | 2 |
| Book Value | 1.085 |
| City | King of Prussia |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.13 |
| Current Ratio | 8.386 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 1.15 |
| Day Low | 1.11 |
| Display Name | Phio Pharmaceuticals |
| Dividend Date | 1,579,046,400 |
| Earnings Timestamp End | 1,755,518,400 |
| Earnings Timestamp Start | 1,754,996,340 |
| Ebitda | -13,470,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.01 |
| Enterprise Value | 131,492 |
| Eps Current Year | -1.445 |
| Eps Forward | -0.61 |
| Eps Trailing Twelve Months | -1.29 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.05458 |
| Fifty Day Average Change | 0.07542002 |
| Fifty Day Average Change Percent | 0.07151665 |
| Fifty Two Week Change Percent | -47.16981 |
| Fifty Two Week High | 4.19 |
| Fifty Two Week High Change | -3.06 |
| Fifty Two Week High Change Percent | -0.73031026 |
| Fifty Two Week Low | 0.813 |
| Fifty Two Week Low Change | 0.31699997 |
| Fifty Two Week Low Change Percent | 0.38991386 |
| Fifty Two Week Range | 0.813 - 4.19 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,336,656,600,000 |
| Float Shares | 11,505,492 |
| Forward Eps | -0.61 |
| Forward P E | -1.852459 |
| Free Cashflow | -7,724,250 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 6 |
| Fullday Change | 0.00999999 |
| Fullday Change Percent | 0.892856 |
| Fullday Price | 1.12 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -8,532,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.03944 |
| Held Percent Institutions | 0.10208 |
| Implied Shares Outstanding | 11,617,251 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,720,137,600 |
| Last Split Factor | 1:9 |
| Long Business Summary | Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was founded in 2003 and is based in King Of Prussia, Pennsylvania. |
| Long Name | Phio Pharmaceuticals Corp. |
| Market | us_market |
| Market Cap | 13,127,494 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_140969529 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -12,904,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 13,011,320 |
| Number Of Analyst Opinions | 1 |
| Open | 1.12 |
| Operating Cashflow | -12,202,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 610 947 0251 |
| Post Market Change | -0.00999999 |
| Post Market Change Percent | -0.8849549 |
| Post Market Price | 1.12 |
| Post Market Time | 1,787,957,415 |
| Previous Close | 1.12 |
| Price Eps Current Year | -0.78200686 |
| Price Hint | 4 |
| Price To Book | 1.0414746 |
| Profit Margins | 0.0 |
| Quick Ratio | 7.622 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | 0.00999999 |
| Regular Market Change Percent | 0.892856 |
| Regular Market Day High | 1.15 |
| Regular Market Day Low | 1.11 |
| Regular Market Day Range | 1.11 - 1.15 |
| Regular Market Open | 1.12 |
| Regular Market Previous Close | 1.12 |
| Regular Market Price | 1.13 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 88,290 |
| Return On Assets | -0.65769994 |
| Return On Equity | -1.1370701 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 11,617,250 |
| Shares Percent Shares Out | 0.0275 |
| Shares Short | 319,747 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 177,615 |
| Short Name | Phio Pharmaceuticals Corp. |
| Short Percent Of Float | 0.0277 |
| Short Ratio | 0.25 |
| Source Interval | 15 |
| State | PA |
| Symbol | PHIO |
| Target High Price | 14.0 |
| Target Low Price | 14.0 |
| Target Mean Price | 14.0 |
| Target Median Price | 14.0 |
| Total Cash | 12,996,000 |
| Total Cash Per Share | 1.119 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.29 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.135735 |
| Two Hundred Day Average Change | -0.0057350397 |
| Two Hundred Day Average Change Percent | -0.005049628 |
| Type Disp | Equity |
| Volume | 88,290 |
| Website | https://phiopharma.com |
| Zip | 19,406 |